Micropulse: The Early Results Are In

Cyclophotocoagulation (CPC) is an effective form of cycloablative therapy, but it has been associated with numerous risks and considered a treatment of last resort. Dr. Jonathan Myers discusses the Micropulse (Iridex), a new transscleral diode laser CPC platform that appears to have a better safety profile than its predecessor. The Micropulse shows good pressure reduction and success rates ranging from 50% to 80%. The incidence of reported side effects is low, with cystoid macular edema and loss of 2 or more lines of BCVA the most common.